Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease
Abstract Background We examined the incidence and predictors of clinical outcomes in metabolic dysfunction‐associated fatty liver disease (MAFLD), focusing on anthropometric parameters. Methods Adult patients with MAFLD were identified in nationwide databases and a hospital cohort. Primary endpoints...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.13351 |
| _version_ | 1797375104225640448 |
|---|---|
| author | Kyu Yeon Choi Tae Yeon Kim Young Eun Chon Mi Na Kim Joo Ho Lee Seong Gyu Hwang Jiwoo Lee Mi Kyung Kwak Eun‐Gyoung Hong Yun Mi Choi Yeonjung Ha |
| author_facet | Kyu Yeon Choi Tae Yeon Kim Young Eun Chon Mi Na Kim Joo Ho Lee Seong Gyu Hwang Jiwoo Lee Mi Kyung Kwak Eun‐Gyoung Hong Yun Mi Choi Yeonjung Ha |
| author_sort | Kyu Yeon Choi |
| collection | DOAJ |
| description | Abstract Background We examined the incidence and predictors of clinical outcomes in metabolic dysfunction‐associated fatty liver disease (MAFLD), focusing on anthropometric parameters. Methods Adult patients with MAFLD were identified in nationwide databases and a hospital cohort. Primary endpoints were atherosclerotic cardiovascular disease (ASCVD) and advanced fibrosis. Logistic and Cox regression analyses were used to analyse the association between anthropometric parameters and endpoints. Results In total, 4407 of 15 256 (28.9%) and 6274 of 25 784 subjects (24.3%) had MAFLD in the nationwide database; of these, 403 (9.2%) and 437 (7.0%) subjects were of lean/normal weight, respectively. Compared to the overweight/obese group, the lean/normal weight group had a significantly lower muscle mass (15.0 vs. 18.9 kg) and handgrip strength (31.9 vs. 35.1 kg) and had a higher ASCVD risk (9.0% vs. 6.3% and 15.9% vs. 8.5%; Ps < 0.001). Sarcopenia (odds ratio [OR], 6.66; 95% confidence interval [CI], 1.79–24.80) and handgrip strength (OR, 0.92; 95% CI, 0.86–0.97; Ps = 0.005) were associated with the ASCVD risk in the lean/normal weight group. In a hospital cohort (n = 1363), the ASCVD risk was significantly higher in the lean/normal weight group than in the overweight/obese group (median follow‐up, 39.1 months). Muscle mass was inversely correlated with the ASCVD risk (hazard ratio [HR], 0.72; 95% CI, 0.56–0.94), while visceral adiposity was associated with advanced fibrosis (HR, 1.36; 95% CI, 1.10–1.69; Ps < 0.05). Conclusions Muscle mass/strength was significantly associated with the ASCVD risk in patients with MAFLD. Visceral adiposity was an independent predictor of advanced fibrosis. |
| first_indexed | 2024-03-08T19:17:23Z |
| format | Article |
| id | doaj.art-50c5df4af48b44cd921732a2fc7a6056 |
| institution | Directory Open Access Journal |
| issn | 2190-5991 2190-6009 |
| language | English |
| last_indexed | 2024-03-08T19:17:23Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Cachexia, Sarcopenia and Muscle |
| spelling | doaj.art-50c5df4af48b44cd921732a2fc7a60562023-12-27T05:05:03ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092023-12-011462747275610.1002/jcsm.13351Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver diseaseKyu Yeon Choi0Tae Yeon Kim1Young Eun Chon2Mi Na Kim3Joo Ho Lee4Seong Gyu Hwang5Jiwoo Lee6Mi Kyung Kwak7Eun‐Gyoung Hong8Yun Mi Choi9Yeonjung Ha10Department of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaDepartment of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaDepartment of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaDepartment of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaDepartment of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaDepartment of Gastroenterology, CHA Gumi Medical Center CHA University Gumi South KoreaDepartment of Endocrinology and Metabolism, Hallym University Dongtan Sacred Heart Hospital Hallym University College of Medicine Hwaseong South KoreaDepartment of Endocrinology and Metabolism, Hallym University Dongtan Sacred Heart Hospital Hallym University College of Medicine Hwaseong South KoreaDepartment of Endocrinology and Metabolism, Hallym University Dongtan Sacred Heart Hospital Hallym University College of Medicine Hwaseong South KoreaDepartment of Endocrinology and Metabolism, Hallym University Dongtan Sacred Heart Hospital Hallym University College of Medicine Hwaseong South KoreaDepartment of Gastroenterology, CHA Bundang Medical Center CHA University Seongnam South KoreaAbstract Background We examined the incidence and predictors of clinical outcomes in metabolic dysfunction‐associated fatty liver disease (MAFLD), focusing on anthropometric parameters. Methods Adult patients with MAFLD were identified in nationwide databases and a hospital cohort. Primary endpoints were atherosclerotic cardiovascular disease (ASCVD) and advanced fibrosis. Logistic and Cox regression analyses were used to analyse the association between anthropometric parameters and endpoints. Results In total, 4407 of 15 256 (28.9%) and 6274 of 25 784 subjects (24.3%) had MAFLD in the nationwide database; of these, 403 (9.2%) and 437 (7.0%) subjects were of lean/normal weight, respectively. Compared to the overweight/obese group, the lean/normal weight group had a significantly lower muscle mass (15.0 vs. 18.9 kg) and handgrip strength (31.9 vs. 35.1 kg) and had a higher ASCVD risk (9.0% vs. 6.3% and 15.9% vs. 8.5%; Ps < 0.001). Sarcopenia (odds ratio [OR], 6.66; 95% confidence interval [CI], 1.79–24.80) and handgrip strength (OR, 0.92; 95% CI, 0.86–0.97; Ps = 0.005) were associated with the ASCVD risk in the lean/normal weight group. In a hospital cohort (n = 1363), the ASCVD risk was significantly higher in the lean/normal weight group than in the overweight/obese group (median follow‐up, 39.1 months). Muscle mass was inversely correlated with the ASCVD risk (hazard ratio [HR], 0.72; 95% CI, 0.56–0.94), while visceral adiposity was associated with advanced fibrosis (HR, 1.36; 95% CI, 1.10–1.69; Ps < 0.05). Conclusions Muscle mass/strength was significantly associated with the ASCVD risk in patients with MAFLD. Visceral adiposity was an independent predictor of advanced fibrosis.https://doi.org/10.1002/jcsm.13351cardiovascular diseasefatty liverfibrosismetabolic dysfunctionsarcopeniavisceral adiposity |
| spellingShingle | Kyu Yeon Choi Tae Yeon Kim Young Eun Chon Mi Na Kim Joo Ho Lee Seong Gyu Hwang Jiwoo Lee Mi Kyung Kwak Eun‐Gyoung Hong Yun Mi Choi Yeonjung Ha Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease Journal of Cachexia, Sarcopenia and Muscle cardiovascular disease fatty liver fibrosis metabolic dysfunction sarcopenia visceral adiposity |
| title | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease |
| title_full | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease |
| title_fullStr | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease |
| title_full_unstemmed | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease |
| title_short | Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease |
| title_sort | impact of anthropometric parameters on outcomes in asians with metabolic dysfunction associated fatty liver disease |
| topic | cardiovascular disease fatty liver fibrosis metabolic dysfunction sarcopenia visceral adiposity |
| url | https://doi.org/10.1002/jcsm.13351 |
| work_keys_str_mv | AT kyuyeonchoi impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT taeyeonkim impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT youngeunchon impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT minakim impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT jooholee impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT seonggyuhwang impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT jiwoolee impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT mikyungkwak impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT eungyounghong impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT yunmichoi impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease AT yeonjungha impactofanthropometricparametersonoutcomesinasianswithmetabolicdysfunctionassociatedfattyliverdisease |